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Summary
Objective: The transcription factor SOX9 has been shown to be linked to chondrocyte differentiation and induction of type II collagen synthe-
sis. Since the chitinase-like protein, human cartilage glycoprotein 39 (HC-gp39), can be expressed by articular chondrocytes and has been
shown to enhance chondrocyte mitogenesis through MAP kinase and PI3 kinase-mediated signalling, we hypothesized that it may also pro-
mote synthesis of cartilage matrix components through induction of SOX9, utilizing similar signalling pathways.
Methods: Primary chondrocytes from neonatal mouse rib cartilage were exposed to puriﬁed HC-gp39. The response of the cells was evalu-
ated in terms of SOX9 induction and synthesis of type II collagen. Signalling pathways activated following HC-gp9 exposure were analyzed by
Western blotting of cell lysates with phosphorylation-speciﬁc antibodies as well as by using selective inhibitors.
Results: HC-gp39 induced both SOX9 and type II collagen synthesis. Similar results were observed for IGF-1. This process required signalling
through both MAP kinase and PI3 kinase pathways resulting in rapid phosphorylation of ERK1/2 and AKT, respectively. Neither HC-gp39 nor
IGF-1 induced activation of SAPK/JNK.
Conclusions: The effects of HC-gp39 on chondrocyte function suggest that this molecule may promote the maintenance or expression of
a chondrocytic phenotype. Its expression in injured or degenerate cartilage could be related to the initial repair-response and increased matrix
synthesis observed in osteoarthritic cartilage.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Chondrocytes secrete a wide variety of proteins involved
in the maintenance of the cartilage matrix in order to
maintain the mechanical properties necessary for normal
joint loading and to counteract joint stresses (overloading,
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Received 29 November 2005; revision accepted 9 July 2006.138overuse, etc.). These unique biomechanical properties rely
mostly on the presence of type II collagen and aggrecan,
a high molecular weight proteoglycan, in the matrix,
which can only be secreted by highly differentiated
chondrocytes.
The coexpression of the transcription factor SOX9,
a member of the HMG-domain transcription family, with
type II collagen and aggrecan during mouse development
suggests its major role in chondrogenic differentiation1,2.
The evidence that SOX9 plays a role in chondrogenesis
came with the identiﬁcation of heterozygous mutations in
and around SOX9 in human patients with campomelic dys-
plasia, a severe form of chondrodysplasia3. Moreover, ge-
netic alterations of the SOX9 gene cause severe skeletal
abnormalities and haploinsufﬁciency of SOX9 results in car-
tilage defects4,5. Type II collagen expression is tightly linked
to SOX9 expression since SOX9 binds to the ﬁrst intron of
the gene inducing its expression6. In vitro, SOX9 expres-
sion is positively regulated by members of the ﬁbroblast
growth factor family7, while pro-inﬂammatory cytokines
like IL-18 decrease its expression. A better understanding
of the balance between the positive and the negative regu-
lators of SOX9 expression is needed to elucidate its role in
cartilage homeostasis and in the attempt to repair observed
at early stages of osteoarthritis (OA)9. The maintenance of
a differentiated chondrocyte phenotype, deﬁned by its ca-
pacity to synthesize adequate quantities of matrix proteins,
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not only in the aim of chondroprotection, but also in the
various cartilage engineering modalities for repair of carti-
lage defects. Transplantation of autologous chondrocytes
expanded in vitro is now used routinely 10, but the efﬁ-
cacy of this therapeutic approach needs to be improved
by enhancing the differentiation state of the transplanted
cells11.
Human cartilage glycoprotein 39 (HC-gp39 also known
as YKL-40 or ChiL-1) belongs to the family of chitinase-
like lectins (chi-lectins), which are found in vertebrates as
well as invertebrates12e15. HC-gp39 is a secreted glycopro-
tein initially identiﬁed in articular chondrocytes and overex-
pressed in arthritic cartilage and in synovial tissues12,16e18.
HC-gp39 levels are increased in sera from OA and rheuma-
toid arthritis patients. A positive correlation between HC-
gp39 levels and disease activity was noted19e21 along
with its decrease following treatment. Thus, serum levels
of HC-gp39 could be a prognostic marker for the progres-
sion of OA or rheumatoid arthritis22,23.
Recent work has shown that HC-gp39 can be considered
as a growth factor, since it stimulates proliferation of human
synovial cells and fetal lung ﬁbroblasts through activation of
protein kinase B and the extracellular signal-regulated
kinase (ERK1/2)emitogen-activated protein kinase signal-
ling pathways24. Moreover, it has been recently demon-
strated that HC-gp39 is able to inhibit cellular responses
to the inﬂammatory cytokines interleukin 1 and tumor necro-
sis factor-alpha25. The identity of the cellular receptors me-
diating the biological effects of HC-gp39 is currently not fully
described. HC-gp39 could be a lectin that binds chitin-like
oligosaccharides26.
We hypothesized that HC-gp39 could play a role in chon-
drocyte differentiation by initiating SOX9 expression in artic-
ular chondrocytes. We conﬁrm this hypothesis by showing
the induction of type II collagen as well as SOX9 protein ex-
pressions. Moreover, we demonstrate that the induction of
SOX9 expression depends on ERK1/2 and PI3K activities,
but not on p38 and JNK MAPK.
Materials and methods
MATERIALS
HC-gp39 was puriﬁed from culture supernatants of hu-
man articular chondrocytes as described previously12 and
its purity was assessed by SDS/PAGE and staining with
Coomassie Brilliant Blue. Molar concentrations for the puri-
ﬁed preparations were calculated based on a molecular
mass of 42 kDa. The biological activity of the puriﬁed mate-
rial was assessed by its capacity to activate protein kinase
B in skin ﬁbroblasts27. Puriﬁed HC-gp39 was stored frozen
at 20C in aliquots to avoid repeated freeze-thawing and
denaturation of the protein.
Recombinant human insulin-like growth factor-1 (IGF-1)
was purchased from Roche Diagnostics (Meylan, France).
SB203580, PD98059, U0126 and JNK inhibitor were ob-
tained from Calbiochem (Meudon, France). LY294002
was obtained from Ozyme for Cell Signalling Technology
(Saint Quentin en Yvelines, France). Anti-goat SOX9 and
anti-goat type II collagen antibodies were obtained from
Te´bu for Santa Cruz biotechnology (Le Perray en Yvelines,
France). Anti-rabbit phospho-AKT (Ser 473) (catalog no
#9271), anti-rabbit AKT (catalog no #9272), anti-rabbit
phospho-p38 MAP kinase (Thr 180/Tyr 182) (catalog no
#9211), anti-rabbit p38 MAP kinase (catalog no #9212),
anti-mouse phospho-p44/42 MAPK (Thr 202/Tyr 204)(catalog no #9106), anti-rabbit p44/42 MAPK (catalog no
#9102), anti-rabbit phospho SAPK/JNK (Thr 183/Tyr 185)
(catalog no #9251), and anti-rabbit SAPK/JNK (catalog no
#9252) antibodies were purchased from Ozyme for Cell Sig-
nalling Technology (Saint Quentin en Yvelines, France).
The anti-mouse b-actine monoclonal antibody was pur-
chased from SigmaeAldrich (Saint Quentin Fallavier,
France). The enhanced chemiluminescence (ECL) detec-
tion system for Western-blot analysis was purchased from
Amersham Biosciences (Orsay, France).
All reagents for cell culture were purchased from Sig-
maeAldrich (Saint Quentin Fallavier, France). Fetal bovine
serum was from Invitrogen (Cergy Pontoise, France).
CHONDROCYTE CULTURES
All the experiments were performed according to proto-
cols approved by the French/European ethical committee.
Mouse costal chondrocytes were obtained from 2 to
4-day-old mice as described previously28. The suspended
chondrocytes were seeded in 100-mm dishes (1 106 cells
per dish) in DMEM medium containing penicillinestrepto-
mycin 1%, glutamine 2% and supplemented with 10% fetal
calf serum. The cells were maintained at 37C in 5% CO2,
and the culture medium was changed every 2 days. The
cells were almost conﬂuent in 6 days.
SAMPLE PREPARATION FOR PROTEIN STUDIES
Cells were grown to conﬂuence in 100-mm dishes and
rendered quiescent by starving them of serum for 24 h, us-
ing DMEM supplemented with 0.1% bovine serum albu-
min. Cells were stimulated by adding medium containing
or lacking agonists at 37C for the indicated time, unless
otherwise indicated. The exposure to agonists or vehicle
was terminated by rapidly washing twice with 5 ml of ice-
cold PBS. For MAPK studies, cells were scraped into
500 ml lysis buffer (20 mM Tris, pH 7.6, 0.15 M NaCl,
2 mM EDTA, 1% Triton, 10% glycerol, 50 mM sodium ﬂuo-
ride, 1 mM sodium orthovanadate, 2 mM sodium pyrophos-
phate, 1 mM p-aminoethylbenzenesulfonyl ﬂuoride, 10 mg/
ml leupeptin, 1 mg/ml antipain, 1 mg/ml pepstatin A), kept
on ice for 20 min, and then vortexed for 1 min. The cell de-
bris were removed by centrifugation at 13,000g for
10 min at 4C, and the total protein content was deter-
mined photometrically using bicinchoninic acid (Micro-
BCA kit, Pierce).
ELECTROPHORESIS AND WESTERN BLOTTING
Aliquots (20e50 mg) of clariﬁed total proteins were sepa-
rated by SDS-PAGE, on 10% or 8% running gels, in 25 mM
TriseHCl, 190 mM glycine, 0.1% SDS, pH 8.3. The sepa-
rated proteins were electroblotted on to Protan BA83
nitrocellulose membranes (Schleicher & Schuell). The
membranes were soaked in 10 mM TriseHCl, pH 7.5,
100 mM NaCl, 0.1% Tween 20, 5% serum albumin at
room temperature for at least 2 h. MAPKs activation was
assayed by incubating the nitrocellulose blots overnight at
4C with an antiserum that speciﬁcally recognizes the phos-
phorylated forms of p42 and p44 MAPK, p38 MAPK or JNK
MAPK. Stripped blots were also probed with an antiserum
recognizing both the unphosphorylated (inactive) and phos-
phorylated (active) forms to check the application of equal
amounts of lysate.
The membranes were washed and incubated with goat
anti-rabbit IgG conjugated to horseradish peroxidase.
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Fig. 1. HC-gp39 and IGF-1 increase SOX9 and type II collagen protein levels in chondrocytes. Mouse primary chondrocytes were cultured and
grown to conﬂuence and serum starved for 24 h followed by incubation in the presence or absence of 1 mg/ml HC-gp39 or/and 25 ng/ml IGF-1.
Total cell lysates were examined by Western-blot analysis using antibodies that recognize SOX9, type II collagen and b-actin. The ﬁgure pres-
ents data from one of the four independent experiments that produced similar results.Immunoreactive bands were detected using the ECL West-
ern blotting detection system, and Biomax MR1 ﬁlm (Sigma)
exposed for 10e90 s. When necessary, the blots were strip-
ped for 40 min at 52C in a Tris buffer containing 62.5 mM
Tris, 2% SDS, 100 mM mercaptoethanol, 0.1% sodium
azide adjusted to pH 7.4. AKT, SOX9 and type II collagen
were immunodetected in an analogous manner, using the
appropriate antibodies.Results
HC-gp39 AS WELL AS IGF-1 INCREASES SOX9 PROTEIN
LEVELS IN PARALLEL WITH TYPE II COLLAGEN PROTEIN
EXPRESSION IN MOUSE PRIMARY CHONDROCYTES
We ﬁrst examined the effects of HC-gp39 and IGF-1 on
SOX9 protein levels in mouse primary chondrocytes. HC-
gp39 (1 mg/ml) increased the levels of SOX9 proteinP-ERK1 (p44)
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Fig. 2. Time course of HC-gp39- and IGF-1-induced ERK1/2 phosphorylation. (A) Mouse primary chondrocytes were grown to conﬂuence and
serum starved for 24 h, followed by exposure to 1 mg/ml HC-gp39 for times ranging from 0 to 60 min as indicated. Total cell lysates were
examined by Western-blot analysis using antibodies that recognize ERK-1 and ERK-2, their Tyr 204 phosphorylated forms (p-ERK1 and
p-ERK2) and b-actin. The ﬁgure presents data from one of the four independent experiments that produced similar results. (B) Mouse primary
chondrocytes were grown to conﬂuence and serum starved for 24 h, followed by exposure to 25 ng/ml IGF-1 for times ranging from 0 to 60 min
as indicated. Total cell lysates were examined by Western-blot analysis using antibodies that recognize ERK-1 and ERK-2, their Tyr 204 phos-
phorylated forms (p-ERK1 and p-ERK2) and b-actin. The ﬁgure presents data from one of the four independent experiments that produced
similar results.
141Osteoarthritis and Cartilage Vol. 15, No. 2expression after 24 h of stimulation (Fig. 1). This increase
of SOX9 protein expression paralleled the increase of type
II collagen protein expression. IGF-1 (25 ng/ml), a well-
known growth factor for cartilage matrix, was able to in-
crease, in the same manner, SOX9 and type II collagen
protein expressions (Fig. 1). Interestingly, the addition of
both HC-gp39 and IGF-1 showed an additive effect on
SOX9 protein expression but not on type II collagen protein
expression.
In order to elucidate the signalling pathways involved in
SOX9 expression by HC-gp39 and IGF-1, we analyzed
MAPK and AKT signalling pathways, known to be involved
in growth factor-mediated transduction in chondrocytes.
HC-gp39 AND IGF-1 INDUCE PHOSPHORYLATION OF ERK1/2
AND AKT IN A TIME-DEPENDENT MANNER IN MOUSE
CHONDROCYTES
Exposure of serum-starved chondrocytes to either HC-
gp39 [Fig. 2(A)] or IGF-1 [Fig. 2(B)] resulted in rapid
phosphorylation of ERK1/2, detectable as early as 2 min
after addition of the reagents. Phosphorylation appeared
to have reached maximal levels at this early time point
and slowly decreased back to basal levels over the
next 30 min.
The time course of AKT phosphorylation in response to
exposure of the cells to HC-gp39 [Fig. 3(A)] showed a
proﬁle similar to that of ERK1/2, a maximum effect oc-
curred at 2 min and then phosphorylation decreased
down to the basal level by 30 min. The time course ofAKT phosphorylation in response to exposure to IGF-1
[Fig. 3(B)] showed an increase at 2 min which is main-
tained until 60 min.
LACK OF p38 MAPK AND SAPK/JNK PHOSPHORYLATION
IN RESPONSE TO HC-gp39 OR IGF-1 TREATMENT
Whereas the non-phosphorylated form of p38 MAPK was
detected in mouse chondrocytes, neither IGF-1 nor HC-
gp39 was able to induce phosphorylation of p38 MAPK
(Fig. 4). Mouse chondrocytes exposed to anisomycin
(50 mg/ml) were used as a positive control. A strong band
representing the phosphorylated form of p38 was detect-
able by Western blotting, indicating that the antibody was
able to recognize this protein in mouse chondrocytes.
In the same manner, neither IGF-1 nor HC-gp39 was able
to induce phosphorylation of SAPK/JNK in mouse chondro-
cytes (Fig. 5). A non speciﬁc band was detected around
50 kDa (Fig. 5). A positive response was observed in
mouse primary chondrocytes exposed to anisomycin
(50 mg/ml).
INHIBITION OF ERK1/2 PHOSPHORYLATION DECREASES
SOX9 AND TYPE II COLLAGEN PROTEIN LEVELS IN
CHONDROCYTES
In order to determine if the phosphorylation of ERK1/2 by
HC-gp39 and IGF-1 was involved in the expression of
SOX9 and type II collagen induced by these factors, cells
were stimulated in the presence of U0126, a selectivePhospho-AKT
HC-gp39 :
IGF-1 :
0 2 5 10 30 60 (min)
+ + + + +
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+ + + + +
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Fig. 3. Time course of HC-gp39- and IGF-1-induced AKT phosphorylation. (A) Mouse primary chondrocytes were grown to conﬂuence and
serum starved for 24 h, followed by exposure to 1 mg/ml HC-gp39 for times ranging from 0 to 60 min as indicated. Total cell lysates were
examined by Western-blot analysis using antibodies that recognize AKT, its phosphorylated form p-AKT and b-actin. The ﬁgure presents
data from one of the three independent experiments that produced similar results. (B) Mouse primary chondrocytes were grown to conﬂuence
and serum starved for 24 h, followed by exposure to 25 ng/ml IGF-1 for times ranging from 0 to 60 min as indicated. Total cell lysates were
examined by Western-blot analysis using antibodies that recognize AKT, its phosphorylated form p-AKT and b-actin. The ﬁgure presents data
from one of the three independent experiments that produced similar results.
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Fig. 4. p38 MAPK is neither phosphorylated by HC-gp39 nor by IGF-1 in chondrocytes. (A) Mouse primary chondrocytes were cultured and
grown to conﬂuence and serum starved for 24 h, followed by exposure to 1 mg/ml HC-gp39 for times ranging from 0 to 60 min as indicated.
Total cell lysates were examined by Western-blot analysis using antibodies that recognize p38-MAPK, its phosphorylated form p-p38 and
b-actin. The ﬁgure presents data from one of the four independent experiments that produced similar results. (B) Mouse primary chondrocytes
were cultured and grown to conﬂuence and serum starved for 24 h, followed by exposure to 25 ng/ml IGF-1 for times ranging from 0 to 60 min
as indicated. Total cell lysates were examined by Western-blot analysis using antibodies that recognize p38-MAPK, its phosphorylated form
p-p38 and b-actin. The ﬁgure presents data from one of the two independent experiments that produced similar results. The lanes marked Cþ
are cell lysates from mouse primary chondrocytes exposed to anisomycin (50 mg/ml), used as a positive control.inhibitor for the upstream kinase 2 MEK 1 and 229 a speciﬁc
inhibitor of ERK1/2. Chondrocytes were exposed to growth
factors in the presence or absence of inhibitor, following
a 1 h pre-treatment with the latter. The increase of SOX9
expression as well as that of type II collagen by HC-gp39
or IGF-1 was strongly reduced in the presence of U0126
(Fig. 6).
LY294002, A SPECIFIC PI3K INHIBITOR, DECREASES SOX9
AND TYPE II COLLAGEN PROTEIN LEVELS IN CHONDROCYTES
In order to know if the phosphorylation of AKT by HC-
gp39 and IGF-1 was involved in the expression of SOX9
and type II collagen, we use LY294002, a speciﬁc and
strong inhibitor of PI3K. After preincubation of mouse chon-
drocytes with inhibitor of 1 h, the growth factors were added
and SOX9 and type II collagen expressions were assessed
at 24 h. The increase of both SOX9 and type II collagen ex-
pressions induced by HC-gp39 or IGF-1 was abolished in
the presence of LY294002 (Fig. 7).
Discussion
We have shown that HC-gp39 markedly enhanced ex-
pression of SOX9 in mouse costal chondrocytes. In parallel
with the increase of SOX9, we observe an increase in
type II collagen expression. Moreover, using adult humanarticular chondrocytes in monolayer culture, we have shown
by PCR that HC-gp39 is able to increase expression of type
II collagen and aggrecan (unpublished data). These data
suggest that in human chondrocytes, as well as in mouse
costal cartilage, HC-gp39 is able to induce the expression
of cartilage-speciﬁc matrix components. This result is in ac-
cordance with the suggested role for SOX9 as a link be-
tween the input of prochondrogenic growth factors and
the expression of chondrocyte-speciﬁc genes needed for
repair. Transfection of SOX9 into OA chondrocytes en-
hances their matrix production30. Moreover, overexpression
of SOX9 in mouse embryonic stem cells directs the imme-
diate chondrogenic commitment31. However, it has been
recently demonstrated that SOX9 is able to exert a bifunc-
tional effect on type II collagen gene expression in chondro-
cytes depending on the differentiation state32. Although
SOX9 has a crucial role in chondrocyte differentiation, this
factor cannot restore the phenotype of osteoarthritic chon-
drocytes by itself. Moreover, no correlation between levels
of SOX9 and type II collagen mRNA expressions has
been found in monolayer culture of human articular chon-
drocytes stimulated with IGF-133 whereas we found a paral-
lel increase of SOX9 and type II collagen protein
expressions in our cells. This discrepancy can be explained
by the origin of the cells in this study that are human adult
chondrocytes, known to do not respond well to growth fac-
tors, particularly IGF-1. Moreover, gene expression array
were performed but no information on the protein level is
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Fig. 5. SAPK/JNK is neither phosphorylated by HC-gp39 nor IGF-1 in chondrocytes. (A) Mouse primary chondrocytes were grown to conﬂu-
ence and serum starved for 24 h, followed by exposure to 1mg/ml HC-gp39 for times ranging from 0 to 60 min as indicated. Total cell lysates
were examined by Western-blot analysis using antibodies that recognize SAPK/JNK, their phosphorylated forms p-SAPK54 and p-JNK46 and
b-actin. The ﬁgure presents data from one of the two independent experiments that produced similar results. (B) Mouse primary chondrocytes
were grown to conﬂuence and serum starved for 24 h, followed by exposure to 25 ng/ml IGF-1 for times ranging from 0 to 60 min as indicated.
Total cell lysates were examined by Western-blot analysis using antibodies that recognize SAPK/JNK, their phosphorylated forms p-SAPK54
and p-JNK46 and b-actin. The ﬁgure presents data from one of the two independent experiments that produced similar results. The lanes
marked Cþ are cell lysates from mouse primary chondrocytes exposed to anisomycin (50 mg/ml), used as a positive control. The asterisk
indicates a band stained non-speciﬁcally by the pan-speciﬁc SAPK/JNK antiserum.provided. So the correlation between SOX9 and type II col-
lagen is not clearly established but it is likely that in adult
cartilage other factors may be required in addition to
SOX9. Our results suggest that SOX9 is a permissive factor
but is not sufﬁcient for a complete type II collagen expres-
sion. Other SOX-family factors such as L-SOX-5 or SOX6could be critical for its expression34,35. Moreover, other tran-
scriptional factors involved in chondrogenesis such as, but
not limited to, Pax1, Pax9, Runx2, Runx3 and c-Maf have
been recently described36 and it could be possible that
HC-gp39 stimulates production of these factors permissive
for induction of col2A1.C IGF-1 gp39 U0126
IGF-1+
U0126
gp39+
U0126
87 kDa SOX-9
180 kDa Type II collagen
Fig. 6. Activation of ERK1/2 is required for induction of SOX9 and type II collagen. At conﬂuency, mouse primary chondrocytes were prein-
cubated for 1 h with or without U0126 (25 mM). Then the cells were stimulated for 24 h in the presence or absence of 1 mg/ml HC-gp39 or/and
25 ng/ml IGF-1. Total cell lysates were examined by Western-blot analysis using antibodies that recognize SOX9, then type II collagen and
ﬁnally b-actin. The ﬁgure presents data from one of the two independent experiments that produced similar results.
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Fig. 7. LY294002, a speciﬁc PI3K inhibitor, decreases SOX9 and type II collagen protein levels in chondrocytes. Mouse primary chondrocytes
were preincubated during 1 h with or without LY294002 (25 mM). Then, the cells were stimulated for 24 h in the presence or absence of 1 mg/ml
HC-gp39 or/and 25 ng/ml IGF-1. Total cell lysates were examined by Western-blot analysis using antibodies that recognize SOX9, then type II
collagen and ﬁnally b-actin. The ﬁgure presents data from one of the two independent experiments that produced similar results.We demonstrate that the induction of SOX9 expression
depends on ERK1/2 and PI3K activities, but not on p38
and JNK MAPK. It has been shown that FGF1 and
FGF2 are able to stimulate expression of SOX9 in mouse
chondrocytes from neonatal rib cartilage7, through the ac-
tivation of ERK1/2. In this work, insulin did not affect SOX9
while in our study IGF-1 was able to increase SOX9. In
fact, the role of MEK-ERK cascade in cartilage differentia-
tion remains controversial. Other studies describe the
MEK-ERK cascade as a negative modulator of cartilage
differentiation. Endogenous ERK activity was observed to
decrease during spontaneous chondrogenesis in micro-
mass cultures of embryonic chick limb mesenchyme
cells37, and epidermal growth factor-induced inhibition of
in vitro chondrogenesis coincided with increased ERK1
phosphorylation38. Furthermore, the MEK inhibitor
PD98059 was reported to enhance cartilage matrix forma-
tion in limb mesenchyme micromass cultures as evi-
denced by collagen II immunostaining and Alcian blue
histochemistry37,39. Seghatoleslami et al.40 reported that
PD98059 elevates type II collagen and SOX9 gene tran-
script levels in C3H10T1/2 cells, as determined by semi-
quantitative reverse transcriptase-PCR analysis. More
recently, it has been described that the MEK-ERK path-
ways functions as a negative regulator of chondrocyte
differentiation in micromass cultures prepared from fronto-
nasal mesenchyme of stage 24/25 chick embryos. In con-
trast, the MEK-ERK cascade acts as a positive regulator
of chondrogenesis in mesenchyme of the stage 24/25
mandibular arch as well as in fronto-nasal mesenchyme
of the stage 28/29 embryo41. So, the response of chondro-
genic cells to experimental MEK-ERK modulation appears
to be context-dependent, varying with the speciﬁc stage of
differentiation at the moment of treatment and the particu-
lar constellation of other signalling pathways that are con-
currently active42. Interestingly, a recent publication by
Yagi et al.43 shows a correlation between SOX9 and
Bcl2 expressions in ﬁbrillated vs non-ﬁbrillated cartilage
from OA patients. The authors demonstrate that SOX9 is
regulated by Bcl244) and that Bcl2 upregulates SOX9
dependent gene expression in chondrocytes. This upregu-
lation was due to the suppression of MEK-ERK1/2. More-
over, the identity and function of transcription factors that
regulate SOX9 gene expression are not well understood.Recently, an analysis of the human SOX9 proximal pro-
moter region showed that CBF (CCAAT-binding factor)
regulates SOX9 promoter through its interaction with two
functional CCAAT boxes45. A recent study also suggests
that SOX9 is able to interact with chromatin and activates
transcription via regulation of chromatin modiﬁcations46.
Phosphorylation of SOX9 by cyclic AMP-dependent pro-
tein kinase A enhances SOX9 ability to transactivate
a Col2a1 chondrocyte-speciﬁc enhancer47. Based on this
work and on our own study, the hypothesis of a role for
HC-gp39 to trigger the expression/activation of C/EBP fac-
tors via Erk1/2 should be tested.
Finally, we show here for the ﬁrst time that PI3 kinase
activity affects expression of SOX9, independent of
whether it is turned on by IGF-1 or HC-gp39. So, the in-
volvement of PI3 kinase in signalling pathway of SOX9
should be helpful to understand the complexity of SOX9
regulation. However, our data in Fig. 7 seem to show
that collagen II expression is almost completely abolished
when chondrocytes are treated with PI3K inhibitor
LY294002, regardless of whether HC-gp39 or IGF-1 is
present. These data could imply that the PI3K/AKT path-
way is required for activation of collagen II expression
even in the presence of SOX9. This is possible because
it’s now well known that SOX9 is a permissive factor for
the chondrogenesis but it’s not sufﬁcient for a complete
type II collagen expression. Other SOX-family factors
such as L-SOX5 and SOX6 could be critical for its expres-
sion34,35. In fact, it has been shown that BMP-2 stimulates
Col2a1 expression by increasing expression of SOX6,
while SOX9 and L-SOX5 are present, but not regulated48.
Moreover, other transcriptional factors involved in chondro-
genesis as, but not limited to, Pax1, Pax9, Runx2, Runx3
and c-Maf have been recently described36 and it could
be possible that these factors could be phosphorylated
and activated by PI3K/AKT pathway.
Our study demonstrates for the ﬁrst time that HC-gp39
markedly enhanced expression of SOX9 in costal chondro-
cytes. The effects of HC-gp39 on chondrocyte function sug-
gest that this molecule may promote the maintenance or
expression of a chondrocytic phenotype. Its expression in
injured or degenerate cartilage could be related to the initial
repair-response and increased matrix synthesis observed in
osteoarthritic cartilage.
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